Apremilast (Otezla®) for psoriatic arthritis.
Apremilist (Otezla®), alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
Rapid Review
| Commenced | Completed | Outcome |
| 24/02/2015 | 03/04/2015 | Full Pharmacoeconomic Evaluation Recommended. |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 01/09/2015 | 29/04/2016 | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.